Skip to main content
SpringerLink
Log in

Correction of Lipid Metabolism Disorders in Diabetes Mellitus with Peptide Drugs

  • Published:
Bulletin of Experimental Biology and Medicine Aims and scope

We studied the effect of peptide drugs deltalicin and Semax on lipid metabolism disturbances in diabetes mellitus. Diabetes mellitus was modeled by single injection of streptozotocin (45 mg/kg) and rats with blood glucose ≥12 mmol/liter were selected for the further experiments. Deltalicin in a dose 100 μg/kg and Semax in a dose 200 μg/kg as well as sulodexide corrected lipid metabolism disorders: the content of total cholesterol, triglycerides, LDL, index of atherogenicity decreased and HDL concentration increased. Deltalicin produced more potent effect on lipid metabolism in rats with diabetes mellitus than sulodexide and Semax, which manifested in a significant decrease in total cholesterol and LDL concentration and index of atherogenicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bondarenko TI, Kutilin DS, Mikhaleva II. Rat tissues antioxidant status correction by peptide delta sleep during physiological aging of the organism. Uspekhi Gerontol. 2014;27(1):98-107. Russian.

    CAS  Google Scholar 

  2. Bondarenko TI, Maiboroda EA, Mikhaleva II, Prudchenko IA. Metabolic Effects of Delta-Sleep Inducing Peptide during Physiological Ageing of the Organism. Eskp. Klin. Farmakol. 2013;76(9):22-26. Russian.

    CAS  Google Scholar 

  3. Endothelial dysfunction. Causes, mechanisms, and drug correction. Petrishchev NN, ed. St. Petersburg, 2003. Russian.

  4. Klimov AN, Nikul’cheva NG. Lipides, Lipoproteids, and Atherosclerosis. St. Petersburg, 1995. Russian

  5. Kutilin DS, Bondarenko TI, Mihaleva II. Influence of delta sleep inducing peptide on the state of lysosomal membranes and intensity of lysosomal proteolysis in different rat tissues at physiological aging of the organism. Uspekhi Gerontol. 2014;27(3):488-495.

    CAS  Google Scholar 

  6. Laboratory methods in clinical practice. Men’shkov VV, ed. Moscow, 1987. Russian.

  7. Spasov AA, Cheplyaeva NI, Lenskaya KV, Snigur GL. The Effect of A Limiglidol on DPP-4 and Morphological Features of Pancreatic Islets in Streptozotocin Diabetes Model. Eksp. Klin. Farmakol. 2015;78(5):8-12. Russian.

  8. Lebedeva MA, Sanotskaya NV, Matsievskii DD. Respiratory and cardiovascular responses to hypoxia under activation or blockade inhibitory transmission. Patol. Fiziol. Eksp. Ter. 2013;57(2):80-84. Russian.

  9. Tyurenkov IN, Voronkov AV, Slietsans AA, Oganesyan ET, Sharenko OM, Andreyeva OA. Effect of flavicin and other flavonoids on carbohydrate and lipid metabolisms in animals with diabetes mellitus. Farmatsiya. 2013;(7):39-41. Russian.

  10. Yasnetsov VV, Voronina TA. Antihypoxic and antiamnesic effects of mexidol and semax. Eksp. Klin. Farmakol. 2010;73(4):2-7. Russian.

  11. Arca M, Pigna G, Favoccia C. Mechanisms of diabetic dyslipidemia: relevance for atherosclerosis. Curr. Vasc. Pharmacol. 2012;10(6):684-686.

    Article  CAS  Google Scholar 

  12. Bulut T, Demirel F, Metin A. The prevalence of dyslipidemia and associated factorsin children adolescents with type I diabetes. J. Pediatr. Endocrinol. Metab. 2017;30(2):181-187.

    Article  Google Scholar 

  13. Hulbert AJ, Turner N, Storlien LH, Else PL. Dietary fats and membrane function: implications for metabolism and disease. Biol. Rev. Camb. Philos. Soc. 2005;80(1):155-169.

    Article  CAS  Google Scholar 

  14. Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015;58(5):886-899.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathophysiology, Kursk State Medical University, Ministry of Health of the Russian Federation, Kursk, Russia

    A. A. Elagina, Yu. D. Lyashev, A. Yu. Lyashev & T. V. Pronyaeva

  2. ABC Medical Imagining, Kornishe Al-Mapraa, Beirut, Lebanon

    A. R. Chahine

Authors
  1. A. A. Elagina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu. D. Lyashev
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Yu. Lyashev
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. V. Pronyaeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. R. Chahine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yu. D. Lyashev.

Additional information

Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 168, No. 11, pp. 556-558, November, 2019

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Elagina, A.A., Lyashev, Y.D., Lyashev, A.Y. et al. Correction of Lipid Metabolism Disorders in Diabetes Mellitus with Peptide Drugs. Bull Exp Biol Med 168, 618–620 (2020). https://doi.org/10.1007/s10517-020-04764-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10517-020-04764-2

Keywords

Search

Navigation